semaglutide prior authorization Wegovy® (semaglutide) Criteria & Form Semaglutide Prior Authorization: A Step-by-Step

Participants received a weekly dose of semaglutide (mean dose 0.8 mg) over an average period of 8.2 months

After a month-long break, a conservative approach often involves restarting at a lower dosetypically the starting dose of 2.5 mg weekly or one step below the previous maintenance dosethen re-escalating according to the standard titration schedule

The medication works systemically once absorbed, and its mechanism of action does not depend on the presence or function of the gallbladder

As evidence regarding the treatment effect of retreatment and the long-term discontinuation of semaglutide 2.4 mg remains limited, further validation will be required as additional clinical and real-world data become available